Author Title [ Type(Asc)] Year
Filters: Author is Juliusson, Gunnar  [Clear All Filters]
Journal Article
Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, Juliusson G, Sutton L-A, Mansouri L. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?. Haematologica. 2015.
Roschupkina T, Juliusson G. Subpopulations of T regulatory cells in blood stem cell harvests influence development of acute graft vs. host disease in allogeneic transplant recipients. Cytometry B Clin Cytom. 2016.
Nilsson C, Hulegårdh E, Garelius H, Möllgård L, Brune M, Wahlin A, Lenhoff S, Frödin U, Remberger M, Höglund M, et al. Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting. Biol Blood Marrow Transplant. 2019.
Juliusson G, Jadersten M, Deneberg S, Lehmann S, Möllgård L, Wennström L, Antunovic P, Cammenga J, Lorenz F, Ölander E, et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv. 2020;4(6):1094-1101.
Bhoi S, Ljungström V, Baliakas P, Mattsson M, Smedby KE, Juliusson G, Rosenquist R, Mansouri L. Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: the case of subset #2. Epigenetics. 2016.
Wålinder G, Samuelsson J, Näsman P, Hansson M, Juliusson G, Forsberg K, Svensson R, Linder O, Carlson K, Kristinsson SY, et al. Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry. Eur J Haematol. 2019.
Gonzalez JMartin, Baudet A, Abelechian S, Bonderup K, D'Altri T, Porse B, Brakebusch C, Juliusson G, Cammenga J. A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines. Genesis. 2018.
Machaczka M, Johansson J-E, Remberger M, Hallböök H, Lazarevic VLj, Wahlin BEngelbrekt, Omar H, Wahlin A, Juliusson G, Kimby E, et al. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse. Med Oncol. 2013;30(4):762.